Characterization and Evaluation of Inhalers, Nebulizers and Nasal devices
Expert Guidance in Characterization and Evaluation of Inhalers, Nebulizers and Nasal devices
By Senior Adviser Mårten Svensson, PhD
At Emmace, we pride ourselves on offering unparalleled expertise and guidance throughout the entire drug product development process. Here’s how we can elevate your project:
Inhalation Technology and
Method Development
- Expert advising in in vitro methodologies designed to predict in vivo outcomes, utilizing anatomically realistic throat models and patient-relevant airflow profiles.
- Development of performance testing protocols. Managing testing of prototypes all the way to late stage in vitro bioequivalence studies.
- Oversee testing and generation of in vitro data in Emmace’s lab. Instruments and methods for rAPSD and Dissolution are up and running and can be used to generate customers in vitro data.
- Evaluation of study data. Expert skills in handling large data sets followed by summary presentations and data visualization.
Leader in multidisciplinary environments
- Proven success in facilitating international collaborations, including Academia and regulatory authorities as well as pharmaceutical/device companies, addressing complex R&D challenges.
- Long experience as a key interface between mechanical engineering teams and analytical scientists in the develop- ment of novel inhalation platforms.
- Input on scientific material: Experienced presenter and author, with numerous peer-reviewed publications, patents, conference posters, and contributions to pharmacopeial standards
Dr. Mårten Svensson has over 20 years of experience in the pharmaceutical industry and industry consortiums. His primary focus has been characterisation of inhalers, nebulizers, and nasal products. After 13 years at big pharma, where he developed in vivo-in vitro correlation methods for inhaled drugs, he founded Emmace Consulting in 2011. Under his leadership, Emmace has become a CRO-lab recognized for its innovative rAPSD methodologies and has contributed to today’s regulatory landscape this bioequivalence route.
